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P16 and p27 tumor suppressor gene methylation status in
childhood Wilms tumor cases
Ceyhun BOZKURT1, Süreyya BOZKURT2, Nilüfer ARDA3, Ayşe Ulya ERTEM1, Gürses ŞAHİN1,
Nazmiye YÜKSEK1, Dicle GÜÇ2, Emin KANSU2

Aim: To analyze the methylation status of the promoter regions of p16 and p27 genes in Wilms tumor patients. These
tumor suppressor genes are associated with 2 main pathways regulating the G1/S transition of the cell cycle.
Materials and methods: Sixteen patients with Wilms tumor were included in the study. The methylation status of CpG
islands in the p16 and p27 genes was analyzed by the polymerase chain reaction (PCR) technique in the tumor tissue
samples obtained from all patients. Five tissue samples of normal kidney were obtained from pathology department
archives.
Results: P16 gene promoter methylation was detected in 2 of 16 (12.5%) patients, one of which was heterozygous and
the other homozygous. P27 gene promoter methylation was also found in 2 of 16 (12.5%) patients, one of which was
heterozygous and the other homozygous. No methylation status was observed in normal kidney tissues.
Conclusion: Our results showed that the incidence of CpG island promoter region methylation of the p16 and p27
tumor suppressor genes in Wilms tumor was low. However, larger series are needed to determine the prognostic value
of DNA methylation of p16 and p27 in Wilms tumor patients.
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Çocukluk çağı Wilms tümör olgularında p16 ve p27 tümör süpressör gen metilasyon
durumu
Amaç: Bu çalışma ile çocukluk çağı Wilms tümörü olgularında p16 ve p27 genlerinin promoter bölgesinin metilasyon
durumlarının incelenmesi amaçlanmıştır. Bu tümör supresör genler hücrenin G1 fazından S fazına geçişini kontrol
eden iki ana yolda rol almaktadır.
Yöntem ve gereç: Bu çalışmaya Wilms tümör tanılı 16 hasta alınmıştır. Tüm hastaların alınan patolojik dokularının p16
ve p27 genlerinin CpG adacık bölgelerinin metilasyon durumu polimeraz zincir reaksiyonu (PCR) ile incelendi. Ayrıca
5 adet normal böbrek dokusu çalışılmak üzere patoloji bölümü arşivinden alındı.
Bulgular: 16 hastanın 2’sinde (% 12,5) p16 gen promoter bölgesinde biri homozigot diğeri heterozigot olmak üzere
metilasyon durumu gözlenmiştir. P27 gen promotor bölgesinde 16 hastanın 2’sinde (% 12,5) biri homozigot diğeri
heterozigot olmak üzere metilasyon gözlenmiştir. 5 adet normal böbrek dokusunda metilasyon gözlenmemiştir.
Sonuç: Çalışmamızda Wilms tümör olgularında p16 ve p27 gene promotor bölge metilasyonu düşük düzeyde
görülmüştür. Düşük olgu sayımız nedeniyle Wilms tümörü olgularında P16 ve P27 gen metilasyonun prognostik
önemini belirlemek için daha geniş serili çalışmalara ihtiyaç vardır.
Anahtar sözcükler: Wilms tümörü, p16 geni, p27 geni, metilasyon, epigenetik
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Introduction
Wilms tumor (WT) is a childhood embryonal
cancer of the kidney. WT is the original model for
studying the etiology of cancer. The functions of the
WT1 and WT2 suppressor genes have been shown in
WT, but a large part of WT etiology is still unknown.
Epigenetics can be defined as a heritable change in
gene expression that is not accompanied by changes
in DNA sequence. Epigenetic dysregulation may
have an important role in cancer initiation and
progression. These epigenetic changes may lead
to activation of genes that increase tumor invasion
and metastasis and inactivation of tumor suppressor
genes (1). An important epigenetic regulation
mechanism is the methylation of the DNA CpG
island. DNA methylation results from the addition
of a methyl group to the carbon 5 position of the
cytosine ring. The methylation of CpG-rich genes
triggers the locking off mechanisms that may turn a
gene off or block its activation (2). DNA methylation
is also important for other mechanisms, such as
mammalian development, embryogenesis, cellular
differentiation, chromosome integrity, and control
of DNA replication and repair (3). As a general rule,
excessive methylation (hypermethylation) and loss
of appropriate methylation (hypomethylation) can
lead to carcinogenesis. Hypermethylation can be
factor via silencing of tumor suppressor genes and
hypomethylation by the inappropriate activation of
or proto-oncogenes.
Cyclin and cyclin-dependent kinases (CDKs)
play an important role in the regulation of cell
cycle progression. The activity of Cyclin-CDK
complexes is regulated by CDK inhibitors. CDK
inhibitors can be divided into 2 groups: the INK4
family, composed of p16, p15, p18, and p19, which
specifically inhibits CDK4 and CDK6 (4), and the
Kip/Cip family, composed of p27, p21, and p57.
A member of the Kip/Cip family is able to inhibit
a wide variety of CDKs (5). P16 and p19 tumor
suppressor genes increase the tumor suppressor
effect of the retinoblastoma (Rb) protein and the p53
tumor suppressor genes, respectively (6). Activated
CDK inhibitors, p16 or p27, bind CDKs that result
in cell cycle arrest (7). Promoter hypermethylation
of p16 inversely correlates with the presence of Rb
mutations in multiple tumors. Hypermethylation634

mediated inactivation of p16 has been demonstrated
in tumors of the brain, breast, colon, head, neck,
and non-small cell lung cancers, and in high-grade
non-Hodgkin’s lymphoma (8). Decreased loss of p27
tumor suppressor function is associated with tumor
invasiveness and negative results in cancer cases,
especially in hepatocellular carcinoma (9). Although
there are some studies on p16 gene methylation in
Wilms tumor cases, the loss of imprinting (LOI) of
the IGF2 gene (which encodes insulin-like growth
factor II) is the most common genetic or epigenetic
alteration in these tumors. Our aim in this study was
to assess the methylation status of the p16 and p27
tumor suppressor genes in Wilms tumor samples.
Materials and methods
Patients and samples: The study was approved
by the institutional ethic committee. The study group
consisted of 16 patients (8 female, 8 male; age range
18 to 87 months; mean age 42 months) with sporadic
Wilms tumor. All patients underwent surgical
resection of the tumor between 1999 and 2007 at
Dr. Sami Ulus Children’s Hospital. Besides these
16 tissue samples from Wilms tumors, 5 normal
kidney tissue samples were obtained as control group
from pathology archives. All patients with Wilms
tumor were staged and treated according to the
Turkish Pediatric Oncology Group Wilms Tumor
Study Protocol. The patients with Wilms tumor
were followed up until April 2009 and they had all
survived to that date. Clinical and histological data
are summarized in the Table.
Molecular analysis
Genomic DNA was extracted from formalinfixed paraffin-embedded tissues following the
deparaffinization procedure, using QIAamp DNA
Mini kit (QIAGEN, Hilder, Germany) according to
the manufacturer’s instructions. Methylation-specific
PCR (MSP) assays were performed to determine
the methylation status of CpG islands in the p16
and p27 gene promoters (11). Before methylationspecific PCR (MSP) assays, DNA samples were
modified with the sodium bisulfate reaction to
convert unmethylated cytosine to uracil according
to the manufacturer’s instructions (CpG Genome
DNA modification kit, Chemicon, Temacula,
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USA). Previously reported primer sequences and
PCR conditions were used to amplify the p16 and
p27 genes (10). For the amplification of the p16
promoter, the DNA was amplified with Taq DNA
(1 unit/50 μL, Fermentas, Vilnius, Lithuania) (PCR
conditions, 35 cycles at 95 °C for 30 s, at 62 °C for 30
s, and at 72 °C for 30 s) giving a 151 bp product for
the unmethylated allele and 150 bp product for the
methylated allele, whereas PCR products specific for
p27 promoter (PCR conditions, 5 cycles at 95 °C for
30 s, at 56 °C for 30 s, and at 72 °C for 30 s) were 195
bp for unmethylated allele and 201 bp for methylated
allele.
CpG genome universal methylated DNA supplied
with the kit was used as positive controls whereas
PCRs performed with water instead of template
DNA was served as PCR-negative controls. DNA
from normal kidney specimens was used as normal
tissue control for unmethylated alleles for each PCR
reaction. PCR products were separated on 2% agarose
gel electrophoresis, stained with ethidium bromide,
and visualized under UV light.

Results
All tumor tissue samples were evaluated to
determine the histological type of Wilms tumor.
No tumor samples had anaplastic criteria. Of the
16 patient tumor samples, 9 had mixed cell, 1 had
the epithelial-mesenchymal, 1 had the epithelialblastemal, 1 had the teratoid, and 1 had the
rhabdomyomatosis subtype of Wilms tumor. It was
not possible to subclassify 3 of the 16 Wilms tumor
specimens while 2 out of 16 patients had additional
urogenital anomalies (horseshoe kidney, hydrocele).
One patient has aniridia. Two patients had a family
history. No tumor samples showed methylation
status (Table).
There was no CPG island methylation in 12 of
the 16 samples. Tumor suppressor methylation was
detected in only 4 samples. One sample (No: 31302) showed homozygous p27 gene methylation and
another sample (No: 290-01) showed heterozygous
p27 gene methylation. In the p16 gene promoter
region methylation evaluation, 1 sample (No:109902) showed heterozygous and another sample (No:

Table. Summary of the clinical and molecular features of Wilms tumor (nonanaplastic) cases.

Sample
no

Sex

Age at
diagnosis
(months)

112-07
390-07
1099-02
313-02
546-02
1288-05

M
F
M
M
M
F

24
60
18
24
30
66

441-06
269-05
579-99
216-03
464-01
615-03
144-97
290-01
167-05
742-07

F
F
F
M
M
F
F
M
M
F

42
54
42
60
36
24
36
20
18
87

Additional
anomaly
----Left hidrocele
Horse shoe
kidney
--------Aniridia
--

Stage Histology

II Mixed cell Wilms tumor
II Mixed cell Wilms tumor
II Mixed cell Wilms tumor
III Wilms tumor
IV Wilms tumor
IV Wilms tumor
III Rhabdomyomatous
III Teratoid Wilms tumor
III Mixed cell Wilms tumor
IV Epithelial-blastemal
III Mixed cell Wilms tumor
II Mixed cell Wilms tumor
III Mixed cell Wilms tumor
III Mixed cell Wilms tumor
III Epithelial-mesenchymal
IV Mixed cell Wilms tumor

Outcome

p16

p27
Tumor

Familiy
History

Alive
Alive
Alive
Alive
Alive
Local
relapse
Alive
Alive
Alive
Alive
Alive
Alive
Alive
Alive
Alive
Alive

UM
UM
HtM
UM
UM
HtM

UM
UM
UM
HM
UM
UM

-------

UM
UM
UM
UM
UM
UM
UM
UM
UM
UM

UM
UM
UM
UM
UM
UM
UM
HtM
UM
UM

--------+
+

Abbrevations: M:Male, F:Female, UM:Unmethylated, HtM:Heterozygous methylated, HM:Homozygous methylated
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It was previously thought that an alteration of DNA
methylation occurred only as a part of carcinogenesis.
However, it is now thought that it is not a secondary
result of cancer as alteration of DNA methylation
has been shown in the precancerous event. To the
contrary, it can facilitate the development of cancer
(12).

genes. DNA hypomethylation can cause genetic
dysregulation via genetic instability (13). The
tumor suppressor gene methylation status affects
tumor progression. The hypermethylation status of
tumor suppressor genes generally leads to tumor
progression. However, some studies have shown
that hypomethylation of tumor suppressor genes
also affects tumor progression. Hypomethylation
of the promoter region of DNA CpG islands has
also been shown in rhabdomyosarcoma, Hodgkin
lymphoma, and anaplastic large cell lymphoma
(14,15). This methylation was thought to lead to
tumor progression. Nevertheless, Nishiyama et al.
(16) demonstrated that cytosine residues of the
NBL2 gene subregion in ovarian cancer cells showed
both hypermethylation and hypomethylation status.
Erlich et al. (17) observed general hypomethylation at
CpG islands but also found hypermethylation at local
CpG islands. These interesting changes show some
variance in the first tumor cell population and may
cause tumor cell heterogeneity and more aggressive
tumor cell clones (1).

DNA hypomethylation and hypermethylation
are important in the activation of tumor suppressor

There are many studies about the facilitating role
of CpG island hypermethylation in the initiation

1288-05) showed homozygous p16 gene promoter
region methylation (Figure). The patient with
horseshoe kidney (No: 1288-05) and relapsed Wilms
tumor had a homozygous p16 gene methylation.
Discussion
Epigenetic alterations may increase the
vulnerability of the genome to genetic changes and are
environmental carcinogenesis. Decreased function
of the tumor suppressor genes may also result from
epigenetic changes in the DNA structure, such as
mutations, rearrangements, and gene amplifications
(11).

1

Figure.

2

3

4

5

6

7

8

9

10

11

12

13

14

Methylation-specific PCR gel of p16 tumor suppressor genes.
1- 50 base pair marker.
2- Unmethylated band of the p16 gene that belongs to sample 1099.
3- Methylated band of the p16 gene that belongs to sample 1099.
6- Unmethylated band of the p16 gene that belongs to sample 141.
8- Unmethylated band of p16 gene that belongs to normal kidney sample.
10- No DNA p16 unmethylated band.
11- No DNA p16 unmethylated band.
13- Methylated band of p16 gene that belongs to positive control.
14- 50 base pair marker.
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of tumor formation and tumor progression. The
inactivation of multiple tumor suppressor genes
leads to dysregulation of the cell cycle control
and subsequently tumor development. The tissue
proliferation index was found to be high during
the evaluation of the methylation status of the p16
gene, one of the tumor suppressor genes with an
important role in intracellular signal transduction
in hepatocellular carcinoma (9) and lymphoma (18).
Chim et al. (19) found that p16 gene methylation
was associated with a higher lymphocyte count in
chronic lymphocytic leukemia patients. Higher levels
of p16 gene methylation appear to increase the risk
of hepatocellular and colorectal cancer progression
(9,20). The p27 tumor suppressor gene plays an
important role in the intracellular signal conduction
system. It is thought that low levels of the p27 gene
are not a cause but a result of carcinogenesis and that
this low level affects the progression of the disease
(7). Kawauchi et al. (21) found a higher tumor
proliferation index in germ cell tumors with high
p27 tumor gene methylation status. Qian et al. (22)
showed methylation of the p27 tumor suppressor
gene in some pituitary cell tumors leading to silencing
of the p27 tumor suppressor gene.
WT1 and WT2 gene-related pathology is the first
known gene pathology of Wilms tumor. However,
this gene pathology is found in only 15% of Wilms
tumor cases. Investigators have therefore searched
for the presence of any other pathology other than
those related to the WT1 and WT2 genes. P53 is
a well-known tumor suppressor gene and is also
responsible for some familial cancers. Mutations in
the p53 tumor suppressor gene were found in 75%
of patients with anaplastic Wilms tumors in a study
(23). Methylation of the p16 tumor suppressor gene
was detected in 22.9% of patients, none of whom
had the protein product. There was also no statistical

relationship between the methylation status of the p16
tumor suppressor gene and the tumor progression
and stage (24). Arcellana-Panlilio et al. (25) reported
that methylation of the p16 tumor suppressor gene
was present in 9 of 38 Wilms tumor tissues and half
of these patients had advanced disease stages. They
thought that methylation of the p16 tumor suppressor
gene might be an important prognostic sign in Wilms
tumor. We did not detect methylation of the p16 and
p27 tumor suppressor genes in 87.5% of the tumor
tissues in our study. However, statistical analysis was
not performed due to the relatively small sample
size. Interestingly, one patient with a horseshoe
kidney and relapsed tumor showed homozygous p16
methylation. This finding reminded us of the study
by Arcellana-Panlilio et al. (25) indicating that the
p16 methylation status of the tumor may be related
to poor prognosis. However, our p16 methylation
status results are consistent with those of the
Faussillon et al. (26) and Morris et al. (27) studies
on Wilms tumor cases. In terms of the evaluation
of methylation status of the p27 tumor suppressor
gene, it seems that p27 methylation does not play an
important role in Wilms tumor cases. Our findings
regarding p27 methylation are consistent with those
of Kawauchi et al. (22) in malignant germ cell tumor,
of Brakensiek et al. (28) in myelodysplastic syndrome
and acute myeloid leukemia, and of Chim et al. (29)
in chronic lymphocytic leukemia. This low level may
be attributed to an activated post-transcriptional
degradation mechanism, such as the ubiqutinproteasome pathway (30). Our results suggest that
the methylation of the p16 and p27 tumor suppressor
gene promoter region is at a low level and there is
no correlation with the clinical stage. However, larger
patient series are needed to determine the prognostic
value of the p16 and p27 gene methylation status in
Wilms tumors.
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